Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

O-024

Supelco

Olanzapine solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C17H20N4S
CAS-Nummer:
132539-06-1
Molekulargewicht:
312.43
EG-Nummer:
200-835-2
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

certified reference material

Qualitätsniveau

300

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

1.0 mg/mL in acetonitrile

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

clinical testing

Format

single component solution

Lagertemp.

−20°C

SMILES String

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChIKey

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Angaben zum Gen

human ... DRD2(1813) , DRD3(1814) , DRD4(1815) , HTR2A(3356) , HTR2C(3358)

Verwandte Kategorien

Allgemeine Beschreibung

An analytical reference standard for use in LC/MS or GC/MS applications including clinical toxicology analysis or therapeutic drug monitoring. Marketed under the trade name Zyprexa®, olanzapine is an atypical antipsychotic drug used in the treatment of schizophrenia and bipolar disorder.

Anwendung

  • Metabolic impact of Olanzapine in bipolar disorder: A network meta-analysis of randomized-controlled trials assessed the metabolic effects of antipsychotics and mood stabilizers, including Olanzapine, in patients with bipolar disorder, providing insights into its pharmacodynamic properties and implications for treatment optimization (Kong et al., 2024).
  • Machine learning in schizophrenia research: Olanzapine′s effectiveness was evaluated through a systematic review employing machine learning to predict violent behaviors in schizophrenia spectrum disorders. This study underscores the relevance of antipsychotic treatment profiling in enhancing patient-specific therapeutic strategies (Delvecchio et al., 2024).
  • Solubility and bioavailability enhancement: Research focused on the evaluation of polymeric matrices for loading poorly water-soluble drugs, like Olanzapine, into mesoporous silica. This study advances the development of more effective and bioavailable oral liquid formulations of Olanzapine (Barmpalexis et al., 2024).

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zyprexa is a registered trademark of Eli Lilly and Co.

Piktogramme

FlameExclamation mark
GHS02,GHS07

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 2

Flammpunkt (°F)

35.6 °F - closed cup

Flammpunkt (°C)

2 °C - closed cup

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Heating under high-frequency inductive conditions: application to the continuous synthesis of the neurolepticum olanzapine (Zyprexa).
Jan Hartwig et al.
Angewandte Chemie (International ed. in English), 52(37), 9813-9817 (2013-07-31)
Jean A Milstein et al.
PloS one, 8(2), e57308-e57308 (2013-02-26)
Antipsychotic drugs are increasingly used in children and adolescents to treat a variety of psychiatric disorders. However, little is known about the long-term effects of early life antipsychotic drug treatment. Most antipsychotic drugs are potent antagonists or partial agonists of
Stephen M Stahl et al.
The Journal of clinical psychiatry, 74(5), 507-515 (2013-04-02)
The primary objective was to evaluate the safety and tolerability of lurasidone, a new atypical antipsychotic agent, in the longer-term treatment of schizophrenia (DSM-IV). Persistence of symptom improvement was assessed as a secondary outcome. Patients who completed a 6-week, double-blind
Chantal Henry et al.
BMC psychiatry, 13, 79-79 (2013-03-21)
One of the major issues in clinical practice is the accurate differential diagnosis between mixed states and depression, often leading to inappropriate prescriptions of antidepressants in mixed states, and as a consequence, increasing the risk of manic switch and suicide.
A case of atypical antipsychotic-induced somnambulism: a class effect.
Yael Dagan et al.
The Journal of clinical psychiatry, 74(4), 370-370 (2013-05-10)
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.